Fernand Labrie

Publications

Page 3 of 25, showing 50 records out of 1234 total, starting on record 101, ending on 150

Publication Category Year
1134. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J.L., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J. (2006) Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol, 103: 178-88. All publications 2006
1133. Labrie, F., Luu-The, V., Martel, C., Chernomoretz, A., Calvo, E., Morissette, J., Labrie, C. (2006) Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol, 100: 52-8. All publications 2006
1132. Yoshioka, M., Boivin, A., Ye, P., Labrie, F., St-Amand, J. (2006) Effects of dihydrotestosterone on skeletal muscle transcriptome measured by serial analysis of gene expression. J Mol Endocrinol, 36: 247-259. All publications 2006
1131. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2006) Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia. Metabolism, 55: 605-13. All publications 2006
1130. Labrie, F., Poulin, R., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (2006) Androgens, DHEA and Breast Cancer, in: Tulandi, T. et Gelfand, M.M., eds: Androgens and Reproductive Aging, Oxsfordshire, UK, pp 113-135. All publications 2006
1129. Tchédam Ngatcha, B., Laplante, Y., Labrie, F., Luu-The, V., Poirier, D. (2006) 3 beta-Alkyl-androsterones as inhibitors of type 3 17 beta-hydroxysteroid dehydrogenase: Inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR(+) and ER(+) cell lines. Mol. Cell Endocrinol, 248: 225-232. All publications 2006
1128. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. All publications 2005
1127. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. All publications 2005
1126. Berger, L., El-Alfy, M., Martel, C., Labrie, F. (2005) Effects of DHEA, Premarin and Acolbifene on histomorphology and sex steroid receptors of the rat vagina. J Steroid Biochem Mol Biol, 96: 201-15. All publications 2005
1125. Tchédam Ngatcha, B., Luu-The, V., Labrie, F., Poirier, D. (2005) Androsterone 3β-Ether-3β-Substituted and Androsterone 3β-Substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem., 48: 5257-5268. All publications 2005
1124. Azzi, L., El-Alfy, M., Martel, C., Labrie, F. (2005) Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J Invest Dermatol, 124: 22-7. All publications 2005
1123. Gauthier, S., Cloutier, J., Dory, Y.L., Favre, A., Mailhot, J., Ouellet, C., Schwerdteeger, A., Mérand, Y., Martel, C., Simard, J., Labrie, F. (2005) Synthesis and structure-activity relationships of analogs of EM-652 (acobifene), a pure selective estrogen receptor modulator. Study of mitrogen substitution. J of Enzyme Inhibition and Medicinal Chemistry, 20: 165-177. All publications 2005
1122. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Cianflone, K., Deshaies, Y. (2005) Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-B1 and LDL receptors. J. of Lipid Research, 46: 1285-94. All publications 2005
1121. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2005) The selective estrogen receptor modulator acolbifene reduces cholesterolemia idependently of its anorectic action in control and cholesterol-fed rats. J Nutr, 135: 2225-9. All publications 2005
1120. Lemieux, C., Phaneuf, D., Labrie, F., Giguère, V., Richard, D., Deshaies, Y. (2005) Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes, 29: 1236-44. All publications 2005
1119. Ye, P., Yoshika, M., Labrie, C., Lin, G., Raymond, V., Morissette, J., Labrie, F., St-Amand, J. (2005) Regulation of global gene expression by ovariectomy and estrogen in female white adipose tissue. Obes Res, 13: 1024-30. All publications 2005
1118. Soucy, G., Boivin, G., Labrie, F., Rivest, S. (2005) Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol, 174: 6391-8. All publications 2005
1117. Samson, M., Labrie, F., Luu-The, V. (2005) Inhibition of human-type 1 3β-hydroxysteroid deshydrogenase/Δ5-Δ4-isomerase expression using siRNA. J Steroid Biochem Mol Biol, 94: 253-7. All publications 2005
1116. Pelletier, G., Luu-The, V., Li, S., Labrie, F. (2005) Localization of type 7 17β-hydroxysteroid dehydrogenase mRNA in mouse tissues. In situ hybridization studies. J Steroid Biochem Mol Biol, 93: 49-57. All publications 2005
1115. Pelletier, G., Luu-The, V., Li, S., Labrie, F. (2005) Localization of type 5 17β-hydroxysteroid dehydrogenase mRNA in mouse tissues as studies by in situ hybridization. Cell Tissue Res., 320: 393-8. All publications 2005
1114. Pelletier, G., Luu-The, V., Li, S., Labrie, F. (2005) Localization of type 8 17β-Hydroxysteroid Dehydrogenase mRNA in Mouse Tissues as Studied by In Situ Hybridization. J. Histochem. & Cytochem., 53: 1257-1271. All publications 2005
1113. Pelletier, G., Lihrmann, I., Dubessy, C., Luu-The, V., Vaudry, D., Labrie, F. (2005) Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. Neuroscience, 132: 689-696. All publications 2005
1112. Maltais, R., Mercier, C., Labrie, F., Poirier, D. (2005) Solid-phase synthesis of model libraries of 3alpha, 17β-dihydroxy-16alpha-(aminoethyl-N-substituted)-5alpha-androstanes for the development of steroidal therapeutic agents. Molecular Diversity, 9: 67-79. All publications 2005
1111. Luu-The, V., Pelletier, G., Labrie, F. (2005) Quantitative appreciation of steroidogenic gene expression in mouse tissue: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol, 93: 269-76. All publications 2005
1110. Labrie, F., Luu-The, V., Calvo, E., Martel, C., Cloutier, J., Gauthier, S., Belleau, P., Boucher, H., Morissette, J., Lévesque, M.H., Labrie, C. (2005) Tetrahydrogestrione (THG) induces a genomic signature typical of a potent anabolic steroid. J Endocrinol, 184: 427-33. All publications 2005
1109. Dosa, L., Sandler, H.M., Labrie, F., Kane, C. (2005) Prostate cancer management shows major shift in PSA era. Urol Times, 33: 9. All publications 2005
1108. Dinel, S., Bolduc, C., Belleau, P., Boivin, A., Yoshioka, M., Calvo, E., Piedboeuf, B., Snyder, E.E., Labrie, F., St-Amand, J. (2005) Reproducibility bioinformatic analaysis and power of SAGE method to evaluate changes in transcriptome. Nucleic Acids Res., 33:e26: 1-8. All publications 2005
1107. Couture, J.-F., Pereira de Jésus-Trans, K., Roy, A.-M., Cantin, L., Côté, P.-L., Legrand, P., Luu-The, V., Labrie, F., Breton, R. (2005) Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen. Protein Science, 14: 1485-1497. All publications 2005
1106. Schaid, D.J., Chang, B.L., The International Consortium for Prostate Cancer Genetics. (2005) Description of the International Consortium for Prostate Cancer Genetics, and failure to replicate Linkage of Hereditary Prostate Cancer to 20q13. The Prostate, 63: 276-290. All publications 2005
1105. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. All publications 2004
1104. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. All publications 2004
1103. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. All publications 2004
1102. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. All publications 2004
1101. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. All publications 2004
1100. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. All publications 2004
1099. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. All publications 2004
1098. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17β-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. All publications 2004
1097. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. All publications 2004
1096. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. All publications 2004
1095. Tchernof, A., Labrie, F. (2004) Dehydroepiandrosterone, obesity and cardiovascular disease risk. A review of human studies. European Journal of Endocrinology, 151: 1-14. All publications 2004
1094. Sancéau, J.-Y., Labrie, F., Gauthier, S. (2004) Synthesis of 14C-labelled EM-800 (SCH 57050) and EM-652. HCI (SCH 57068. HCI, acolbifene), pure selective estrogen receptor modulators. J. of Label Compounds & Radiopharmaceuticals, 47: 741-752. All publications 2004
1093. Pelletier, G., Luu-The, V., Li, S., Ren, L., Labrie, F. (2004) Localization of 17β-hydroxysteroid dehydrogenase type 1 mRNA in mouse tissues. J.Mol Endocrinol, 33: 459-465. All publications 2004
1092. Pelletier, G., Luu-The, V., Li, S., Ouellet, J., Labrie, F. (2004) Cellular localization of mRNA Expression of Enzymes Involved in the Formation and Inactivation of Hormonal Steroids in the Mouse Prostate. J. Histochem & Cytochem., 52: 1351-1356. All publications 2004
1091. Pelletier, G., Luu-The, V., Li, S., Labrie, F. (2004) Localization and estrogenic regulation of androgen receptor mRNA expression in the mouse uterus and vagina. J Endocrinol, 180: 77-85. All publications 2004
1090. Pelletier, G., Luu-The, V., Li, S., Labrie, F. (2004) Localization of 20 alpha-hydroxysteroid dehydrogenase mRNA in mouse brain by in situ hybridization. Molecular Brain Research, 125: 143-146. All publications 2004
1089. Lepine, J., Bernard, O., Plante, M., Tetu, B., Pelletier, G., Labrie, F., Bélanger, A., Guillemette, C. (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J. of Clinical Endocrinology and Metabolism, 89: 5222-5232. All publications 2004
1088. Leblanc, M., Bélanger, M.C., Julien, P., Tchernof, A., Labrie, C., Bélanger, A., Labrie, F. (2004) Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal and combined androgen blockade conditions. J. of Clinical Endocrinology and Metabolism, 89: 1849-1857. All publications 2004
1087. Larose, M., St-Amand, J., Yoshioka, M., Morissette, J., Labrie, C., Raymond, V., Labrie, F. (2004) Transcriptome of mouse uterus by Serial Analysis of Gene Expression: comparison with skeletal muscle. Mol Reprod Dev, 68: 142-148. All publications 2004
1086. Labrie, F., Candas, B. (2004) Author Response: The Quebec Screening Study Shows a 62% Decrease in Prostate Cancer Death. The Prostate, 61: 373-374. All publications 2004
1085. Labrie, F. (2004) Adrenal Androgens and Intracrinology, in: Bruce R. Carr, M.D., eds. Seminars in Reproductive Medicine, New York - Stuttgart, pp 299-309. All publications 2004
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards